Project Grant RF1NS146420
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $566,529 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective April 24, 2026, with completion targeted for March 31, 2031. The award funds research investigating age-related deficits in trophic support of dopamine neurons in preclinical models of...
- Federal Project Grant Award Summary Colorado State University received a $2,674,385 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded August 15, 2025, with completion targeted for July 31, 2029. This research initiative investigates structure-function relationships in alpha-synuclein protein strains using cryo-electron microscopy (cryo-EM)...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1.81M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 11, 2026, with completion targeted for April 30, 2029. The award funds research investigating leucine-rich repeat kinase 2 (LRRK2) signaling pathways and their role in Parkinson's...
- Federal Project Grant Award Summary Northwestern University's Sponsored Research Division received a $634,938 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2026 through May 31, 2031. This five-year research initiative investigates RNA editing dysregulation in the pathogenesis of dementia and Parkinson's disease, specifically...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a $155,000 project grant effective July 8, 2025 through June 30, 2027 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports the characterization of an aminoacyl-tRNA synthetase complex interacting multifunctional protein-2 (AIMP2) variant-linked mouse model of Parkinson's disease. The...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $541,750 Project Grant to the San Diego Biomedical Research Institute on May 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), with a completion date of April 30, 2028. The grant funds research to discover noncanonical autophagy modulators for Alzheimer's disease and related dementias, including frontotemporal degeneration...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $670,266 effective January 20, 2026, through December 31, 2030, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to map the epigenomic and spatial transcriptomic landscape in Parkinson's Disease (PD) and Alzheimer's Disease (AD). The...
- Federal Project Grant Award Summary The University of Alabama at Birmingham received a $2.72 million Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded June 1, 2025, with a completion date of May 31, 2027. This award funds investigator-initiated research examining the effects of 14-3-3 theta protein phosphorylation on vesicular transport and...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $627,103 Project Grant to the Research Foundation For Mental Hygiene, Inc. (operating as the New York State Psychiatric Institute) effective June 1, 2026, through May 31, 2031, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research investigates the role of the adaptive immune system in Parkinson's disease...
- Federal Grant Award Summary Brigham and Women's Hospital received a $557,883 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective May 1, 2026 through April 30, 2031. The award funds basic neuroscience research investigating the pathogenic mechanisms of leucine-rich repeat kinase 2 (LRRK2) mutations, which are associated with familial...
Rush University Medical Center received a $1,212,318 Project Grant awarded June 25, 2026, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The grant supports a three-year research initiative (completion date May 31, 2029) investigating the role of phosphorylated alpha-synuclein (PS129) in synucleinopathy pathogenesis, with particular focus on the olfactory system and olfactory bulb as proposed initial sites of disease onset. The research aims to elucidate molecular mechanisms of alpha-synuclein aggregation and identify novel therapeutic targets for synucleinopathies—a class of neurodegenerative diseases including Parkinson's disease and Lewy body dementia. The deliverables under this award include scientific research products addressing three core objectives: determining PS129's influence on alpha-synuclein seeding and spread within the olfactory system; differentiating physiological versus aggregated PS129 protein interactions in the olfactory bulb; and examining PS129's role in alpha-synuclein protein quality control mechanisms. The research employs innovative techniques applied to novel synucleinopathy disease models and human olfactory bulb tissue. Expected outcomes include peer-reviewed publications, characterization of molecular pathways driving alpha-synuclein accumulation in the olfactory system, and identification of therapeutic intervention points to support treatment development for synucleinopathies.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 6/30/26 |